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Abstract
Background: The effect of peginterferon and ribavirin treatment on chronic hepatitis C virus (HCV) infection has
been established in several controlled clinical studies. However, the effectiveness of treatment and predictors of
treatment success in routine clinical practice remains to be established. Our aim was to estimate the effectiveness
of peginterferon and ribavirin treatment in unselected HCV patients handled in routine clinical practice. The
endpoint was sustained virological response (SVR), determined by the absence of HCV RNA 24 weeks after the end
of treatment.
Methods: We determined the proportion of SVR in a nationwide, population-based cohort of 432 patients with
chronic HCV infection who were starting treatment, and analyzed the impact of known covariates on SVR by using
a logistic regression analysis.
Results: The majority of treated patients had genotype 1 (133 patients) and genotype 2/3 (285 patients) infections,
with 44% and 72%, respectively, obtaining SVR. Other than genotype, the predictors of SVR were age ≤ 45 years at
the start of treatment, completion of unmodified treatment, the absence of cirrhosis and non-European origin.
Conclusions: The effectiveness of peginterferon and ribavirin treatment for chronic hepatitis C in a routine clinical
practice is comparable to that observed in controlled clinical trials, with a higher SVR rate in genotype 2 and 3
patients compared to genotype 1 patients. Our data further indicate that age at start of treatment is a strong
predictor of SVR irrespective of HCV genotype, with patients 45 years or younger having a higher SVR rate.
Background
Combination therapy with peginterferon and ribavirin
has improved treatment response in patients with
chronic hepatitis C virus (HCV) infection, but the virus
is still only eradicated in 50-80% of the patients receiv-
ing treatment [1-3], depending on HCV genotype.
Treatment is lengthy and has severe side effects, which
may lead to dose reduction or even prevent treatment
completion. There are also several contraindications to
starting treatment, such as ongoing psychiatric disease
or active intravenous drug use (IDU). Progress has been
made in the development of new direct-acting antiviral
drugs, specifically targeting viral replication, and some
of these antivirals have recently been studied in clinical
trials. The results are promising especially for certain
protease inhibitors expected to be licensed soon for the
treatment of chronic HCV infection, as part of triple
therapy with peginterferon and ribavirin [4]. It is, how-
ever, still uncertain when these new agents will be intro-
duced into routine clinical practice.
Most previous studies of antiviral treatment response
in HCV infected patients have included specific and
often highly selected groups of patients (patients in clin-
ical trials, in tertiary hospitals etc.), and these studies
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was found that female gender, young age, being infected
with genotype 2 or 3, absence of cirrhosis, Asian origin
and early inhibition of viral replication predict a better
response to treatment [5-17]. It is however, controversial
whether the promising treatment effects observed in
clinical trials can be transformed into an equivalent
effectiveness in a routine clinical setting, although one
retrospective observational cohort study by Backus et al.
of patients treated in a routine clinical setting at Veter-
ans Affairs facilities showed efficacy of treatment to be
20-52% [12].
The aim of the present study was to estimate the
effectiveness of treatment for chronic HCV infection
with peginterferon and ribavirin in a nationwide, popu-
lation based cohort of HCV infected patients.
Methods
Setting
The prevalence of chronic HCV infection in Denmark
was estimated by the Danish National Board of Health
to be around 0.3% (15,000 individuals) [18]. Approxi-
mately 25% of these individuals are, or have been, moni-
tored in specialized hospital departments, where
antiviral therapy for HCV infection is provided for all
patients found to be in need of treatment.
The Danish Database for Hepatitis B and C (DANHEP)
DANHEP was established in January 2002 as a nation-
wide open cohort study with ongoing enrolment. It
includes data about individuals in Denmark who are
chronically infected with hepatitis B and/or C, are 16
years of age or older, are followed in one of the 11
medical departments that monitor and treat patients
with chronic hepatitis in Denmark, and have been seen
at least once after 1 January 2002 in one of these
departments. The database is described in detail
elsewhere [19].
Tests for HCV RNA and HCV genotype
For 9 of the 11 departments recruiting patients to the
DANHEP study, serum HCV-RNA was quantified in
one laboratory by a previously described RT-PCR
method with a detection limit of 20 IU/mL [20]. Here,
HCV-genotype was determined in RT-PCR with geno-
type specific primers from the 5’ non-coding region of
the virus genome [21]. The remaining two departments
in DANHEP used either COBAS AmpliPrep/COBAS
TaqMan HCV test (Roche diagnostics, Branchburg, NJ)
(detection limit 15 IU/mL), COBAS Amplicor HCV
Monitor (Roche diagnostics) (detection limit 300 IU/
mL) or qualitative HCV-RNA measurements (detection
limit 50 IU/mL) to quantify HCV-RNA and the Versant
HCV Genotyping Assay, LiPA (Bayer HealthCare LCC)
to determine the HCV genotype. Here, genotype was
also, in some cases analyzed using conserved primers
deduced from the core-envelope 1-region of the virus in
RT-PCR followed by sequence analysis [22]. All samples
tested for the presence of HCV RNA 24 weeks after the
end of treatment were tested using one of the methods
with detection limit of 50 IU/mL or lower.
Although HCV genotype 6 is not found in Danish
patients [22], it is widely present in Asia. We therefore
re-analyzed Asian patients found to be infected with gen-
otype 1, if the genotype was determined in RT-PCR with
primers from the HCV 5’ non-coding region, because
this is not a valid method to distinguish genotype 1 from
6. The re-analysis was performed in RT-PCR of the
Core-E1 region and the NS5B-region followed by
sequence analysis of the resulting amplicons [22,23].
Study population
All treatment naive patients, registered in DANHEP
with chronic HCV infection, who started combination
therapy with peginterferon and ribavirin between 1 Jan-
uary 2002 and 1 January 2007, were included in the
study (table 1). Patients were included regardless of
whether they had completed treatment or not, even if
they had only received one dosage of peginterferon.
Patients with positive HBsAg or positive anti-HIV anti-
body test were excluded. In addition, 63 patients were
excluded because HCV-RNA status test at treatment
initiation was not available.
Treatment with either pegylated interferon alpha-2a
(Pegasys
®, Roche A/S, Basel, Switzerland) or alpha-2b
(PegIntron
®, Schering-Plough, Kenilworth, NJ, USA) was
given weekly according to the manufacturer’si n s t r u c -
tions. Ribavirin (Copegus
®, Roche or Rebetol
®, Schering-
Plough) was given daily, adjusted to body weight for
genotypes 1 and 4 or as “flat dosage” for genotypes 2 and
3, according to the manufacturer’s instructions. The
duration of therapy was planned for 48 weeks for geno-
type 1 and 4 and 24 weeks for genotype 2 and 3. Some
patients with genotype 2 or 3 who were included in a
clinical trial were randomized to 12 weeks of treatment
[9]. Other genotype 2 or 3 infected patients participating
in another clinical trial were randomized to 14 or 24
weeks of treatment, if they had a negative HCV-RNA
after 4 weeks [8]. In general, if HCV-RNA titers had not
decreased by a minimum of 2 logs after 12 weeks of
treatment, treatment was stopped according to interna-
tional guidelines.
Study outcome
Treatment outcome was evaluated 24 weeks after end
of treatment, where patients with undetectable HCV-
RNA were categorized as responders, having achieved
sustained virological response (SVR). Patients with
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ment were categorized as non-responders.
Statistics
Logistic regression analyses were used to evaluate poten-
tial predictors of SVR, estimating odds ratios (OR) and
95% confidence intervals (CI). We calculated unadjusted
and adjusted OR with the following covariates included
in the model: Gender, nationality (European vs. Non-
European, route of infection (Intravenous drug use
(IDU) vs. non-IDU), age at treatment initiation (≤ 45
years vs. > 45 years), HCV genotype (genotype 1 vs.
type 2 and 3), ALT at treatment initiation (≤ 2×U N L
vs. > 2 × UNL), HCV-RNA at treatment initiation (≤
600.000 IU/mL vs. > 600.000 IU/mL), and type of
hospital department (Infectio u sD i s e a s e sv s .G a s t r o e n -
terology/Hepatology). We also adjusted for treatment
completion (as scheduled vs. with dose reduction vs.
ended before scheduled) (table 2). For those who had a
liver biopsy performed within 3 years prior to treatment
initiation, we made sub analyses adding the result of the
biopsy to the model; cirrhosis vs. not cirrhosis (META-
VIR score [24]).
Previous studies have shown that patients infected
with genotype 2/3 have a higher response rate to combi-
nation therapy, and we therefore performed the analysis
stratified on HCV genotype (genotype 1 vs. genotype 2/3).
Because only 10 and 2 patients were infected with HCV
genotype 4 and 6, respectively, these patients were not
included in the analyses stratified on HCV genotype.
Starting treatment at a younger age has been asso-
ciated with higher SVR rates [1,6,8,9,25]. Some studies
have included age as a dichotomized variable, while
others have included age in the models as a continuous
variable. We divided the cohort according to age in 10
groups of equal size and made logistic regression ana-
lyses to estimate beta values, to evaluate whether to use
a continuous age scale or a specific cut-off point and if
so, to estimate the best cut-off point. We observed a
sharp drop in beta values between the ages of 43-47,
and therefore age was modeled in the regression analysis
as equal to or less than 45 vs. over 45 years of age at
start of treatment.
Data analyses were performed using SPSS statistical
analysis version 16.0 (SPSS, Chicago, Illinois, USA). The
Study was approved by the Danish Data Protection
Agency (J. nr. 2007-41-0815).
Results
Study population characteristics
In total, 432 chronically infected HCV patients were
included in the study (table 1). Among the 372 patients
of European origin, 327 (87.9%) were Danish. The group
of non-Europeans consisted of 10 African-, 3 American-,
9 Asian-, 15 Pakistani-, and 15 Middle Eastern patients.
Eight patients had an unknown country of origin. Median
age at treatment initiation was 46 years, (range 20-71).
Twenty-eight patients (6.5%) received lower start doses
of peginterferon, ribavirin, or both, than recommended
by the manufacturer.
Genotyping revealed that 133 (30.8%) patients were
infected with genotype 1, 50 (11.6%) with genotype 2,
235 (54.4%) with genotype 3, 10 (2.3%) with genotype 4,
and 2 patients with genotype 6 (0.5%). In 2 patients
(0.5%) the HCV genotype was unknown.
Table 1 Baseline characteristics of 432 patients
chronically infected with HCV, treated with peginterferon
and ribavirin in Denmark between 1 January 2002 and 1
January 2007
Whole cohort
SVR Non-SVR
Total 274 158
Gender Male 177 (64.5) 105 (66.5)
Nationality European 226 (82.5) 146 (92.4)
Non-European 48 (17.5) 12 (7.6)
Route of infection IDU 145 (52.9) 74 (46.8)
non-IDU 37 (13.5) 30 (19.0)
Unknown 92 (33.6) 54 (34.2)
Age at treatment
initiation
≤ 45 years 148 (54.0) 49 (31.0)
Genotype 1 59 (21.5) 74 (46.8)
2 37 (13.5) 13 (8.2)
3 168 (61.3) 67 (42.4)
4 6 (2.2) 4 (2.5)
6 2 (0.7) 0
Unknown 2 (0.7) 0
HCV-RNA > 600.000 IU/mL 92 (33.6) 77 (48.7)
Elevated ALT 2 × UNL* 149 (54.4) 73 (46.2)
Treating
Department
(speciality)
Infectious Diseases 177 (64.6) 101 (63.9)
Gastroenterology/
Hepatology
97 (35.4) 57 (36.1)
Liver biopsy within
3 years
Yes 152 (55.5) 98 (62.0)
Treatment
completion
As planned 193 (70.4) 65 (41.1)
With dose reduction 55 (20.1) 43 (27.2)
Ended before
scheduled
24 (8.8) 39 (24.7)
Unknown 2 (0.7) 11 (7.0)
Data according to those achieving sustained virological response (SVR) versus
non-SVR.
Numbers in parenthesis is % of persons with SVR and non-SVR respectively.
UNL, upper normal limit
*2 × UNL = ALT > 70 IU/L (female), ALT > 100 IU/L (male)
IDU, Intravenous drug use
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ribavirin and predictors of SVR
The overall SVR rate was 63%, with rates of 44%, 74%,
71% and 60% for patients with genotypes 1, 2, 3 and 4,
respectively (table 1). Both patients with genotype 6
infection obtained SVR.
Genotype, age and nationality all had substantial
impact on the fraction of patients who obtained SVR
(table 2). Patients infected with genotype 2/3 had an OR
of 2.3 for SVR compared to genotype 1 and patients
who initiated treatment at age of ≤ 45 years had an OR
of 2.1 for SVR. The impact of age at treatment initiation
was seen for genotype 1 as well as 2/3, although it was
not statistically significant for the latter group (table 3).
Figure 1 shows SVR rates according to age. When ana-
lyzing only the group of patients ≤ 45 years, genotype
was still a predictor of SVR, though not statistically sig-
nificant, while it was a significant predictor of SVR in
the group > 45 years at treatment initiation (table 4).
Also the group of non-Europeans had a significantly
higher SVR rate with an OR of 3.03 for SVR.
In an analysis only including patients who had had a
liver biopsy performed prior to treatment initiation, we
found that cirrhosis was negatively associated with SVR,
Table 2 Unadjusted and adjusted odds ratios and 95% confidence intervals (CI) for sustained virological response
after treatment with peginterferon and ribavirin in 432 chronically HCV infected patients, according to predictor
variables
Predictor variable Odds ratio (95% CI)
unadjusted
Odds ratio (95% CI)
adjusted
Gender Female 11
Male 0.92 (0.61-1.39) 0.80 (0.50-1.27)
Nationality European 11
Non-European 2.53 (1.23-5.21) 3.03 (1.20-7.67)
Route of infection Non-IDU 11
IDU 1.59 (0.91-2.77) 1.43 (0.76-2.69)
Unknown 1.38 (0.77-2.49) 1.21 (0.61-2.41)
Age Age ≤ 45 years at treatment initiation 11
Age > 45 years at treatment initiation 0.38 (0.25-0.58) 0.47 (0.30-0.74)
Genotype 1 11
2o r3 3.01 (1.97-4.60) 2.31 (1.45-3.69)
HCV-RNA ≤ 600.000 IU/mL 11
> 600.000 IU/mL 0.53 (0.36-0.79) 0.70 (0.45-1.10)
ALT Less than 2 × UNL* 1 1
More than 2 × UNL 1.39 (0.94-2.06) 1.40 (0.91-2.16)
Treating department (speciality) Gastroenterology/Hepatology 11
Infectious Diseases 1.03 (0.69-1.55)) 0.93 (0.59-1.49)
Liver biopsy Not cirrhosis 1
Cirrhosis 0.44 (0.25-0.79)
§
Treatment completion As shceduled 11
With dose reduction 0.55 (0.34-0.90) 0.57 (0.33-0.96)
Ended before scheduled 0.22 (0.12-0.38) 0.26 (0.14-0.47)
UNL, upper normal limit
*2 × UNL = ALT > 70 IU/L (female), ALT > 100 IU/L (male)
§Only 250 of the 432 patients had a liver biopsy done. Thisparameter is therefore not included in the adjusted analyses.
IDU, Intravenous drug use
Table 3 Odds ratios and 95% confidence intervals (CI) for
age as predictor of sustained virological response after
treatment with peginterferon and ribavirin in 418
chronically HCV infected patients, divided by genotype
(133 genotype 1, 285 genotype 2/3)
Genotype 1 Genotype 2/3
Odds ratio (95% CI)* Odds ratio (95% CI)*
Age ≤ 45 years 11
> 45 years 0.23 (0.09-0.63) 0.58 (0.33-1.00)
*adjusted for gender, nationality, route of infection, HCV-RNA, ALT, treating
department (gastroenterology/hepatology vs. infectious diseases), treatment
completion as scheduled, ended before scheduled or dose reduction
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adjustment of other co-factors (table 2).
Data available after treatment initiation showed that
dose reduction or stopping treatment before scheduled
were strongly associated with a reduced chance of SVR
(table 2).
Discussion
In a nationwide population based cohort of chronically
infected HCV patients we observed sustained virological
response (SVR) rates of 44% and 72% for genotype 1
and 2/3 respectively, after combination therapy with
peginterferon and ribavirin. Other main predictors of
SVR were age ≤ 45 years at treatment initiation and
completion of non-modified treatment regimens. Finally,
being of Non-European nationality predicted a higher
SVR rate.
While several controlled clinical trials have evaluated
effectiveness of treatment with peginterferon and riba-
virin in HCV infected patients, the effectiveness of treat-
ment in a routine clinical setting is less well shown
[10,25], except for one retrospective, observational
cohort study by Backus et al. with SVR rates of 20%,
52% and 43% in genotypes 1, 2 and 3, respectively,
although the patients included in this study were mainly
men [12]. However, the present study demonstrated that
the effectiveness of treatment, with SVR rates of 44-
72%, is comparable to the SVR rates reported in con-
trolled, clinical trials of genotype 1-3 patients [1,2]. The
unique perspective of the present study is the nation-
wide, population based cohort design and a relatively
large number of genotype 1, 2 and 3 infected patients
included with an almost even distribution of males and
females. As only very few patients in Denmark are trea-
ted at medical departments not participating in the
DANHEP study, our study includes the vast majority of
patients treated for HCV in Denmark during the study
period.
In accordance with observations obtained in con-
trolled, clinical trials we found both genotype and
younger age to be predictors of SVR in patients treated
with peginterferon and ribavirin [1,5,6,25], but to our
knowledge the present study is the only one, based on a
nationwide cohort of unselected patients evenly distribu-
ted between males and females, treated in a routine clin-
ical setting, thus representing an important confirmation
of the effectiveness of treatment with pegylated inter-
feron and ribavirin observed in controlled, clinical trials.
In the present study, infection with genotype 2/3 was a
strong predictor of SVR, also in patients ≤ 45 years,
though statistical significance was not shown in this
group.
In a study by Elefsiniotis et al. [10], genotype was not
found as a predictor of SVR in patients younger than 35
years, and age was not a significant predictor of SVR in
the overall cohort. However, in their analysis, age was
used as a continuous variable. We have not been able to
determine why certain cut off points for age have been
chosen in other studies evaluating age as a predictive
factor of SVR. In the present study, we evaluated
w h e t h e ro rn o ta g ew a sb e s tm o d e l e da sac o n t i n u o u s
variable, or as a design variable dividing age in two
groups. We found that the age of 45 was a relevant cut
off point.
Even though Antonucci et al. [25] only included half
as many patients with genotype 1 and a third as many
with genotype 2/3, as we did, in accordance with our
results, they found that age of < 40 years was a signifi-
cant predictor of SVR in genotype 1 infected patients
treated outside clinical trials. Similarly to Antonucci et
al, we did not find younger age to be a statistically sig-
nificant predictor of SVR in genotype 2/3 infected
patients. In our study however, there was a trend
towards younger age also being a predictor of SVR in
genotype 2/3 (OR: 0.58, 95% CI: 0.33-1.00). Dalgard et
al. [8] and Lagging et al. [9], included 428 and 382
highly selected genotype 2/3 patients, respectively, and
Figure 1 Sustained virological response (SVR) as a function of
age, at antiviral treatment initiation in patients with chronic
hepatitis C. The figure illustrates SVR in the total cohort and SVR
depending on genotype, in different age groups. In all, 274 of 432
achieved SVR. 197 patients were ≤ 45 years (148 achieved SVR) and
235 patients were > 45 years (126 achieved SVR). Of the 133
patients with genotype 1 infection, 47 were ≤ 45 years (30 achieved
SVR), and of the 285 genotype 2/3 infected patients, 144 were ≤ 45
years (113 achieved SVR).
Table 4 Odds ratios and 95% confidence intervals (CI) for
genotype as predictor of sustained virological response
after treatment with peginterferon and ribavirin in 432
chronically HCV infected patients, divided by age
Age ≤ 45 years Age > 45 years
Odds ratio (95% CI)* Odds ratio (95% CI)*
Genotype 1 11
2/3 1.42 (0.62-3.24) 3.00 (1.65-5.47)
*adjusted for gender, nationality, route of infection, HCV-RNA, ALT, treating
department (gastroenterology/hepatology vs. infectious diseases), treatment
completion as scheduled, ended before scheduled or dose reduction
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SVR. Older age at the time of infection is known to be
associated with development of liver fibrosis [26-28].
Patients are carefully selected before initiation of anti-
viral treatment, because the overall treatment outcome
is “poor”, and treatment is lengthy, with many poten-
tially severe side effects. International guidelines on
whom to treat suggest that there should be evidence of
liver fibrosis before treatment initiation in genotype 1
patients [29,30]. Due to the better treatment outcome
and shorter treatment duration, patients infected with
genotype 2 or 3 can start treatment without prior liver
biopsy.
A former study, based on data from DANHEP [19],
showed that patients infected with genotype 2/3, had an
approximately 2.5 times higher chance of starting anti-
viral treatment, while older age at referral was a negative
predictor of treatment initiation. The results in the pre-
sent study, with relatively high SVR rates in genotype 1
patients age 45 or younger, could have implications for
future treatment strategy in this group of patients.
Whether younger patients undergoing the new upcom-
ing treatment regimens that add a specific HCV pro-
tease inhibitor to the standard of care treatment, can
benefit from even shorter treatment periods remains to
be seen. Clearly, further studies are required to establish
the specific indications for treatment initiation in
younger patients. Being infected with HCV has been
shown to decrease quality of life, regardless of disease
progression, and SVR after treatment improves quality
of life [31]. This is another aspect that should be consid-
ered when deciding whether or not to treat patients for
chronic hepatitis C.
Recently, a genetic variation near the IL28B gene on
chromosome 19 was found to be significantly associated
with SVR in HCV infected genotype 1 patients, treated
with peginterferon and ribavirin [32-34]. Ge et al. [32]
found this advantageous genetic variation in 35% of the
cohort examined. Patients with this variation had a 2-3
fold higher rate of SVR than other patients. Around 25-
40% of the patients without the advantageous genetic
variation gained SVR, and the genetic variation was only
associated with an SVR in patients who did not become
HCV RNA negative at week 4 in patients with genotypes
2 and 3 [35]. Therefore it is still important to identify
and use other predictors of SVR when deciding whether
to start treatment for HCV infection. Genetics do not
change with age, therefore the main findings of the pre-
sent study are still very important. It is possible that
patients with genotype 1 HCV infection without the
advantageous IL28B genetic variation, identified in the
studies mentioned above, could benefit from treatment
before the age of 45 years.
The association between being of non-European origin
and the high SVR rate could not be explained from our
data. Thus, further research is needed to elucidate
whether this difference could potentially be related to
IL28B polymorphism differences, as the group of non-
Europeans was diverse ethnically and data on IL28B-
polymorphisms do not exist for all ethnicities involved
in this study.
There are some limitations to the present study. The
study is a retrospective observational study, and we are
lacking information on some potentially important con-
founders such as weight, prior depression, and prior
raised alcohol intake. We did not have any information
on viral kinetics during treatment, and therefore we
could not include this factor in the analyses. Further-
more, we did not have any knowledge of which patients
were treated in clinical trials. It could have been inter-
esting to determine if being treated in a clinical trial was
a predictor of SVR.
Conclusions
We conclude that in a routine clinical practice the treat-
ment effectiveness of patients with chronic HCV with
peginterferon and ribavirin is equivalent to the effective-
ness observed in clinical trials. Furthermore, genotype 2
and 3, age ≤ 45 years at treatment initiation and com-
pletion of a non-modified treatment regimen is strongly
associated with a sustained treatment response. Thus,
our study on a nationwide Danish cohort shed new light
on combination therapy of chronic HCV.
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